Previous close | 3.8000 |
Open | 3.8700 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 2.50 |
Expiry date | 2026-01-16 |
Day's range | 3.8000 - 3.8700 |
Contract range | N/A |
Volume | |
Open interest | N/A |
Erick Lucera, the EVP, Chief Financial Officer of Editas Medicine Inc (NASDAQ:EDIT), sold 22,337 shares of the company on May 20, 2024. Following this transaction, the insider has a total of 116,829 shares remaining in the company. Editas Medicine Inc is a biotechnology company focused on developing transformative gene editing therapies to treat a broad range of diseases.
On May 13, 2024, Jessica Hopfield, Director at Editas Medicine Inc (NASDAQ:EDIT), purchased 45,000 shares of the company, as reported in the SEC Filing.
CAMBRIDGE, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that two abstracts, including one oral presentation and one poster presentation, detailing clinical data from the RUBY and EdiTHAL trials of renizgamglogene autogedtemcel (reni-cel) have been accepted for presentation at the European Hematology Association (EHA) Hybrid Congress being held June 13-16, 2024, in Madrid, Spain, and via livestream. Clinical d